| Abstrakt: |
Objective: To investigate the anti-diabetic effect of the root extract of Annona muricata (AME) in streptozotocin-nicotinamide-induced type 2 diabetic (T2DM) mice. Methods: After 4 weeks of high-fat diet, ICR mice were given 1 g/kg nicotine and 120 mg/kg streptozotocin (STZ) orally to construct a T2DM model. The T2DM mice were randomly divided into five groups: model group, 200 mg/kg metformin group and 50, 100, 200 mg/kg AME groups. Drugs were oral administered continuously for 4 weeks. Fasting blood glucose and body weight were measured weekly. Oral glucose tolerance test (OGTT) and detection of serum glycated hemoglobin (HbA1c) level were performed one week before the end of the experiment. At the end of drug administration, serum total cholesterol (TG), triglycerides (TC), low-density lipoprotein levels (LDL-C) and insulin levels were tested by lipid detection kits; homeostasis model assessment-estimated insulin resistance (HOMA-IR) and HOMA-β indexes were calculated. Liver and kidney tissues were weighed to calculate organ indices and pathological tests were performed. Western blot was performed in the liver to detect adenosine monophosphate-activated protein kinase (AMPK), acetyl coenzyme A carboxylase (ACC), glucose-6-phosphate carboxylase (G6Pase), and phosphoenolpyruvate carboxykinase (PCK1) protein expression. Results: with 200 mg/kg AME significantly reduced fasting blood glucose, HbA1c, TG and LDL-C levels, protected liver and kindey in diabetic mice, decreased the area under the OGTT curve, inhibited ACC and G6Pase protein expressions, and activated AMPK protein expression. Conclusion: AME showed good therapeutic activity against T2DM, and the mechanism may be related to the activation of AMPK and inhibition of ACC and G6Pase proteins. [ABSTRACT FROM AUTHOR] |
